Christina Satterwhite

Author

Pharmaceutical Product Development (United States)

Also Known As

C. Satterwhite, Christina M. Satterwhite, Christina Satterwhite

Publications

536

Citations

H-Index

Concepts

All Affiliations

Pharmaceutical Product Development (United States)Celerion (United States)University of Colorado Colorado Springs Covance (United States)WuXi AppTec (United States)

About

Christina Satterwhite is an author at Pharmaceutical Product Development (United States) specializing in medicine, bioanalysis, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	237
2	Engineering	8	8	191
3	Biochemistry	4	4	101
4	Allergy	1	1	13
5	Biomolecular Engineering	1	1	58

Christina Satterwhite

Publications

475

Citations

H-Index

Page 1

	Year	Citations
ClC-3 Is a Fundamental Molecular Component of Volume-sensitive Outwardly Rectifying Cl− Channels and Volume Regulation in HeLa Cells and Xenopus laevis Oocytes Marcela A. Hermoso, Christina Satterwhite, Yaniré N. Andrade, Journal of Biological Chemistry	2002	104
Functional inhibition of native volume‐sensitive outwardly rectifying anion channels in muscle cells and <i>Xenopus</i> oocytes by anti‐ClC‐3 antibody Dayue Darrel Duan, Juming Zhong, Marcela A. Hermoso, The Journal of Physiology	2001	79
2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV): (Part 3 – Lba, Biomarkers and Immunogenicity) Susan Richards, Lakshmi Amaravadi, Renuka Pillutla, Bioanalysis EngineeringWhite PaperImmunologyBiological Mass SpectrometryPathology	2016	58
Recommendations on qPCR/ddPCR Assay Validation by GCC Mark Wissel, Martin Poirier, Christina Satterwhite, Bioanalysis EngineeringImmunologyDiagnosisPathologyVerification And Validation	2022	47
Chemotactic, mitogenic, and angiogenic actions of UTP on vascular endothelial cells Christina Satterwhite, Angela M. Farrelly, Michael E. Bradley American Journal of Physiology-Heart and Circulatory Physiology ImmunologyVegf TreatmentsCellular PhysiologyVascular Endothelial CellsOxidative Stress	1999	46
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs ( <u>Part 2</u> – Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity) Brian Booth, Lauren Stevenson, Renuka Pillutla, Bioanalysis	2019	31
2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( <u>Part 2A</u> –Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation <u>Part 2B</u> –Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine) Susan Spitz, Yan Zhang, Sally Fischer, Bioanalysis	2021	24
9th GCC Closed Forum: Capa in Regulated Bioanalysis; Method Robustness, Biosimilars, Preclinical Method Validation, Endogenous Biomarkers, Whole Blood Stability, Regulatory Audit Experiences and Electronic Laboratory Notebooks Richard LeLacheur, Isabelle Dumont, Philippe Couerbe, Bioanalysis EngineeringElectronic Laboratory NotebooksBiomarker (Medicine)Translational MedicineBiobank	2016	16
The 10th GCC Closed Forum: Rejected Data, GCP in Bioanalysis, Extract Stability, BAV, Processed Batch Acceptance, Matrix Stability, Critical Reagents, Eln and Data Integrity and Counteracting Fraud Stephanie Cape, Rafiq Islam, Corey Nehls, Bioanalysis Preclinical TherapeuticsMatrix StabilityGlobal Cro CouncilEngineeringVerification And Validation	2017	15
11th GCC Closed Forum: Cumulative Stability; Matrix Stability; Immunogenicity assays; Laboratory Manuals; Biosimilars; Chiral methods; Hybrid LBA/LCMS Assays; Fit-for-Purpose Validation; China Food and Drug Administration Bioanalytical Method Validation Rafiq Islam, Chad Briscoe, Joseph Bower, Bioanalysis ImmunohematologyPreclinical TherapeuticsGlobal Cro CouncilEngineeringCro Members	2018	15

Page 1